Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon alpha-2a therapy in 18 hemangioblastomas.

M Niemelä1, H Mäenpää, P Salven

  • 1Department of Neurosurgery, Helsinki University Central Hospital, Finland. mika.niemela@hus.fi

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 12, 2001
PubMed
Summary

Interferon alfa-2a (IFN-alpha-2a) showed potential in managing asymptomatic hemangioblastomas (HBs) in the central nervous system and retina. While not preventing new growths, it may reduce blood flow in existing HBs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors.

ESMO open·2026
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST).

ESMO open·2021

Area of Science:

  • Oncology
  • Vascular Biology
  • Genetics

Background:

  • Von Hippel-Lindau (VHL) disease is linked to multiple central nervous system (CNS) and retinal hemangioblastomas (HBs), increasing risks for renal cell carcinomas and visceral cysts.
  • Current treatments like microsurgery and radiosurgery are ineffective at preventing new HB formation in VHL patients.
  • Asymptomatic HBs present a therapeutic challenge, necessitating novel treatment strategies.

Purpose of the Study:

  • To evaluate the efficacy of interferon alfa-2a (IFN-alpha-2a) in treating asymptomatic CNS and retinal hemangioblastomas in patients, including those with VHL disease.
  • To assess the antiangiogenic effects of IFN-alpha-2a on HBs and associated visceral cysts.

Main Methods:

  • Four patients (three with VHL) with a total of 15 CNS HBs, 3 retinal HBs, and visceral cysts received subcutaneous IFN-alpha-2a (3 x 10(6) IU, three times/week) for 12 months.

Related Experiment Videos

  • Comprehensive baseline assessments included neurological, ophthalmological, and radiological examinations.
  • Response was monitored through follow-up studies at 3, 13, and 21 months, alongside serum level measurements of vascular endothelial growth factor and erythropoietin.

    • Main Results:

    • No new CNS or retinal HBs were detected during the 12-month IFN-alpha-2a therapy, although one appeared 9 months post-treatment.
    • CNS HBs did not show significant shrinkage, but retinal HBs exhibited shrinkage and reduced leakage, suggesting decreased blood flow.
    • Visceral cysts continued to grow, and serum levels of vascular endothelial growth factor and erythropoietin remained unchanged. No serious adverse events were reported.

    Conclusions:

    • IFN-alpha-2a may offer a therapeutic option for asymptomatic HBs in VHL disease by potentially reducing vascularity, though it does not prevent new lesion formation or affect visceral cyst growth.
    • Further research is warranted to explore the long-term efficacy and optimal use of IFN-alpha-2a in managing VHL-associated HBs.